Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: Implications for Herceptin-mediated therapy

Gynecologic Oncology

Volumn 91, Issue 1, 2003, Pages 231-240

  Bellone, Stefania ^a,c   Palmieri, Michela ^a   Gokden, Murat ^b   Joshua, Jabbar ^a   Roman, Juan J ^a   Pecorelli, Sergio ^c   Cannon, Martin J ^b   Santin, Alessandro D ^a,c,d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

Author keywords

Cervical cancer; HER 2 neu; Herceptin

Indexed keywords

TRASTUZUMAB;

ACCURACY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; EVALUATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE NEU; PRIORITY JOURNAL; TUMOR CELL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

EID: 0141869054     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00460-8     Document Type: Article

References (26)

1. DiSaia PJ, Creasman WT. Clinical gynecologic oncology. Invasive cervical cancer. 5th ed. Mosby-Year Book. 1997, p. 51-106.
2. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1980;707-712.
3. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all erbB receptors, is a mediator of lateral signaling. EMBO J. 16:1997;1647-1655.
4. Padhy L.C., Shih C., Cowing D., Finkelstein R., Weinberg R.A. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell. 28:1982;865-871.
5. Bookman M.A., Darcy K.M., Clarke-Pearson D., Boothby R.A., Horowitz I.R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2 a phase II trial of the Gynecologic Oncology Group . J Clin Oncol. 21:2003;283-290.
6. Tal M., Wetzler M., Josefberg Z., Deutch A., Gutman M., Assaf D., et al. Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res. 48:1988;1517-1520.
7. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer correlation of relapse and survival with amplification of HER-2/neu oncogene . Science. 235:1987;177-182.
8. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50:1990;4087-4091.
9. Oka K., Nakano T., Arai T. c-erbB-2 oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer. 73:1994;664-671.
10. Kihana T., Tsuda H., Teshima S., Nomoto K., Tsugane S., Sonoda T., et al. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer. 73:1994;148-153.
11. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:2001;783-792.
12. Agus D.B., Bunn P.A. Jr, Franklin W., Garzia M., Ozols R.F. HER-2/neu as therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol. 27:2000;53-63.
13. Kristensen G.B., Holm R., Abeler V.M., Trope C.G. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer. 78:1996;433-440.
14. Nakano T., Oka K., Ishikawa A., Morita S. Correlation of cervical carcinoma c-erbB-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. Cancer. 79:1997;513-520.
15. Berchuck A., Rodriguez G., Kamel A., Soper J.T., Clarke-Pearson D.L., Bast R.C. Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina. Obstet Gynecol. 76:1990;381-387.
16. Mark H.F., Feldman D., Das S., Sun C.L., Samy M., Lathrop J. HER-2/neu oncogene amplification in cervical cancer studied by fluorescent in situ hybridization. Genet Test. 3:1999;237-242.
17. Santin A.D., Hermonat P.L., Ravaggi A., Chiriva-Internati M., Zhan D., Pecorelli S., et al. Induction of human papillomavirus-specific CD4+ and CD8+ lymphocytes by E7 pulsed autologous dendritic cells in patients with HPV16 and 18 positive cervical cancer. J Virol. 73:1999;5402-5410.
18. Santin A.D., Ioli G.R., Hiserodt J.C., Rose G.S., Graf M.R., Tocco L.M., et al. Development and characterization of an IL-4-secreting human ovarian carcinoma cell line. Gynecol Oncol. 58:1995;230-239.
19. Hooijberg E., Sein J.J., van der Berk P.C.M., Hart A.A.M., van der Valk M.A., Kast W.M., et al. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and Interleukin 2. Cancer Res. 55:1995;2627-2634.
20. Caligiuri M.A., Murray C., Robertson M.J., Wang E., Cochran K., Cameron C., et al. Selective modulation of human natural killer cells in vivo following prolonged infusion of low-doses recombinant interleukin 2. J Clin Invest. 91:1993;123-128.
21. Pillai R., Balaram P., Nair B.S., Hareendran N.K., Padmanabhan T.K., Nair M.K. Lymphocyte subset distribution after radiation therapy for cancer of the uterine cervix. Possible prognostic implications and correlation with disease course. Cancer. 67:1991;2071-2078.
22. Santin A.D., Hermonat P.L., Ravaggi A., Bellone S., Roman J., Pecorelli S., et al. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. Int J Radiat Oncol Biol Phys. 48:2000;997-1006.
23. Ortaldo J.R., Woodhouse C.S., Morgan A.C. Jr, Herberman R.B., Cheresh D.A., Reisfeld R.A. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies. J Immunol. 138:1987;3566-3572.
24. Honsik C.J., Jung G., Reisfeld R.A. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci USA. 83:1986;7893-7897.
25. Clynes R., Takechi Y., Moroi Y., Houghton A., Ravetch J.V. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA. 95:1998;652-656.
26. Clynes R., Towers T.L., Persta L.G., Ravetch J.V. Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Med. 6:2000;443-446.